< Back to all clusters
[HEALTH] · United States · 3 sources

started · updated

MMP-9 enzyme targeting shows potential in treating diabetic neuropathy

Researchers from UTHealth Houston, the University of Houston, Duke University, McGill University, and other institutions have identified a potential new strategy to combat diabetic neuropathy. According to a study published in Science Translational Medicine, the team focused on the enzyme matrix metalloproteinase-9 (MMP-9).

The researchers developed monoclonal antibodies designed to selectively block MMP-9 activity. In preclinical mouse models with diabetes, the treatment led to a reduction in neuropathic pain, decreased nerve fiber degeneration, and improved wound healing in the paws. Additionally, the study found evidence linking MMP-9 activity to neuropathy in human nerve tissue.

Despite these results, the treatment remains in the preclinical stage. The findings in mice do not yet confirm that the antibody can be used to treat humans or that it can reverse diabetic neuropathy in patients.

Entities

Duke University · McGill University · Science Translational Medicine · UTHealth Houston · University of Houston

Claims

What the coverage asserts, and how many sources carry each claim.